KSKuldeep Sharma

Kuldeep Sharma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kuldeep Sharma has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Do phase change materials (PCMs) contribute to the enhanced performance and functionality of solar stills? A comprehensive analysis

    by Akashdeep Negi, Lalit Ranakoti, Rajesh P. Verma, Prabhakar Bhandari, Shubham Sharma, Kuldeep Sharma, Mohamed Abbas

  • Ag-Based Nanoparticle Synthesis and Its Applications

    by Madhukriti, Arpita Roy, Soumya Pandit, Ashish Kumar, Kuldeep Sharma, Swetha Raj, Vaseem Raja, Hendrix Yulis Setyawan


  • Open Access

    Degradation of Polyaromatic Hydrocarbons by Biosurfactant-Producing Pseudomonas aeruginosa NG4

    by Shivangi Sankhyan, Prasun Kumar, Soumya Pandit, Kuldeep Sharma, Subhasree Ray

    Polyaromatic hydrocarbons (PAHs) are a group of organic pollutants commonly found in the environment due to industrial activities, incomplete burning of fossil fuels, and oil spills. Bioremediation of PAHs has emerged as a promising approach. This study investigated the biodegradation of PAHs (anthracene, naphthalene, phenanthrene, anthraquinone, and anthrone) at 100 ppm to 1000 ppm in the presence of glucose and glycerol by a biosurfactant-producing strain of Pseudomonas aeruginosa NG4. The quality of the biosurfactant produced by the bacterial strain was analyzed via emulsion index (E24), drop-collapse assay, and oil displacement assay. The PAH degradation efficiency was studied by HPLC and degradation metabolites were analyzed using GC-MS. Among all five PAHs (fed at 300 ppm), the highest degradation rates of 91.16 ± 3.64% naphthalene and 41.16 ± 1.64% anthrone were observed by P. aeruginosa NG4 after 10 days of incubation. The assessment of degradation intermediate metabolites revealed the PAH catabolism via the dioxygenase route, which plays a key role in the breakdown of these aromatic compounds. Biodegradation of anthrone by P. aeruginosa NG4 at a 300 ppm level in the media was reported for the first time. This study highlights the potential of P. aeruginosa NG4 as a candidate for the development of bioremediation strategies to mitigate environmental pollution caused by persistent organic pollutants like PAHs.


  • Open Access

    Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine

    by Saif Khan, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, Rama Devi Patel Raja, Shadab Mirza, Kuldeep Sharma, Rajan Verma, Ashish Kumar, Mohtashim Lohani

    Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with a Trop-2-targeting antibody via a pH-sensitive linking moiety, achieving a good drug:antibody ratio. In a phase I-II study involving metastatic TNBC (mTNBC) individuals, SG achieved an overall response rate of 33.3% and a median response period of 7.7 months. The phase III ASCENT trial demonstrated SG’s efficacy in relapsed or refractory TNBC, improving median progression-free survival and median overall survival compared to chemotherapy. Common side effects include neutropenia, nausea, and fatigue. This article highlights the clinical potential, pharmacokinetics, safety profile, and resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-line therapy. The review also discusses current strategies for managing adverse reactions and sequencing ADC treatments in clinical practice, along with the predicted basis of resistance. The optimal sequencing of SG relative to other ADCs, such as trastuzumab deruxtecan or T-DXd, remains an evolving question, especially as newer agents with distinct mechanisms of action and safety profiles enter the field. Further research is essential to establish evidence-based strategies for sequencing SG and addressing disease progression post-ADC therapy.


  • Open Access

    Targeting Refractory Triple-negative Breast Cancer Metastasis with Sacituzumab Govitecan: A new era in Precision Medicine

    by Saif Khan, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, Rama Devi Patel Raja, Kuldeep Sharma, Rajan Verma, Swetha Raj, Ashish Kumar, Mohtashim Lohani

    Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behaviour and limited treatment options. While therapies like checkpoint inhibitors and PARP inhibitors (PARPi) offer some benefit, chemotherapy remains ineffective beyond the first line of treatment. Antibody-drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with a TROP-2-targeting antibody via a pH-sensitive linking moiety, achieving an good drug:antibody ratio. Infused on Days 1 and 8 over 21 days, SG utilizes a moderately stable linker to ensure effective tumor targeting while minimizing side effects like diarrhea. By delivering SN-38 into the tumor niche, it induces double-stranded DNA damage, promoting cancer apoptosis. In a phase I-II study involving 108 mTNBC patients, SG achieved an overall response rate (ORR) of 33.3% and a median response period of 7.7 months. Common side effects included neutropenia, nausea, and fatigue. This review highlights clinical potential, pharmacokinetics, safety profile, resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-line therapy.


  • Open Access

    Numerical simulation of temperature distribution and residual stress in TIG welding of stainless-steel single-pass flange butt joint using finite element analysis

    by Hitesh Arora, Rajeev Kumar, Piyush Gulati, Shubham Sharma, Shashi Prakash Dwivedi, Ambuj Saxena, Abhinav Kumar, Kuldeep Sharma, Dražan Kozak, Anica Hunjet, et al.

    Controlling defects such as deformation in the weld joint and the residual or superfluous stresses due to tungsten inert gas (TIG) welding or arc welding is a major concern for many industries like aeronautical, automobiles, nuclear or atomic power plants, crude oil or fossil fuel industries where pipes are in use and circumferential welding is done. Arc welding is a metal joining process, and TIG welding is applied to many industrial sectors that require high-quality welding. Simulation has been done on single-pass TIG welding on the Flange pipe of SS316 to evaluate transient temperature, residual stresses, and distortion. First, a 3D model is developed and assembled in SolidWorks. Second, in an MSC Patran, preprocessing of the FE model is done. Finally, in MSC Marc, thermal and mechanical simulation is performed. Based on this simulation, the accuracy of welding of the flange–butt joint made of SS316 is validated. In this study, the information regarding simulation of temperature dispensation and residual or superfluous stresses is done on the flange–butt joint, and it found the stresses are compressive at the weld bead area, and along the transverse direction, stresses changed to the tensile. The experimental data show that the steep curve at 0.00 mm represents a maximum temperature near the weld path at approximately 2,352°C, and the slant curve shows the far away points from the weld path. Comparing it with FE analysis, the maximum temperature attained was around 2,539°C. An approximate deviation of 7.365% was observed. The results of the study will provide experimental and simulation analyses for the welding of pipes of stainless steel for the transportation of oil and gases in the petroleum industries.